本帖最后由 maicon08 于 2023-4-28 15:12 编辑 6 w: E3 m. w1 F. |# a1 g7 O& S
1 W$ K! b/ F% h' A, z+ l( n! E
一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国大陆研究Oral Abstract Session入选16项，另外Clinical Science Symposium和Rapid Abstract Session部分各有1项中国研究入选，共18项。
* _' n. z& E; s/ [; T6 u; M* h2 h% X+ W- Z
https://www.163.com/dy/article/I3BTTPRD053438SI.html; ~& r" X4 P x2 N/ M+ a$ k1 x, A- o
1 N( M( Q: m$ a" u' [, b$ h/ r7 [2 J
在研疗法-免疫治疗
0 j2 }7 {7 J. r# u% [( y8 c6 VDevelopmental Therapeutics—Immunotherapy4 C: P& Q) U& s& z. R% o/ P+ G* `
. E# i* I( v8 u8 G
摘要号：2507 标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors. 报告人：丰恺超 单位：JFJ总医院第一医学中心
9 b5 f7 P/ n, V7 b2 o
在研疗法-分子靶向药物和肿瘤生物学$ x! X' h9 d3 f" ?+ F8 k
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology - ?* H E3 F/ {
摘要号：3001 标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 报告人：张力 单位：中山大学肿瘤防治中心 % O' m- d( }9 ?8 ]& g1 |
摘要号：3007 标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. 报告人：周清 单位：广东省人民医院 4 e% }# ^: a( Y4 J4 `, V/ @
胃肠道肿瘤-结直肠癌和肛门癌
6 ]# f: b) V3 g! b+ s Gastrointestinal Cancer—Colorectal and Anal 摘要号：3505 标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. 报告人：张剑威 单位：中山大学附属第六医院 : J' Y( J4 u7 K, y
胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary # b$ S; ]$ I3 U( a
摘要号：4001 标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. 报告人：袁庶强 单位：中山大学肿瘤防治中心 6 I. Y9 ~2 z& w. e
妇科肿瘤 Gynecologic Cancer
" T' B W) u; U8 H摘要号：5516 标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial. 报告人：田文娟 单位：复旦大学附属肿瘤医院 . R& B# d3 }1 k( j" V
头颈肿瘤
/ W' q0 ?1 b% F1 r/ B Head and Neck Cancer
# x; C. X: g6 X9 W摘要号：6000 标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. 报告人：唐林泉 单位：中山大学肿瘤防治中心 w' H. z& X3 w/ x
摘要号：6001 标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. 报告人：陈明远 单位：中山大学肿瘤防治中心
. l: h' D8 W, P1 k4 Q
摘要号：LBA6002 标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). 报告人：马骏 单位：中山大学肿瘤防治中心
9 N9 ?! s6 f2 T, R. M2 X% {$ m
血液系统恶性肿瘤-淋巴瘤和慢性淋巴细胞白血病 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
2 X% Q' y$ O" i8 n, _: S摘要号：7503 标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8). 报告人：蔡清清 单位：中山大学肿瘤防治中心
9 u) G* h W. K. y4 P9 Z; W: U
血液系统恶性肿瘤-浆细胞疾病, a" Z1 [( |/ g. m+ p1 S B
Hematologic Malignancies—Plasma Cell Dyscrasia 8 S7 d3 `8 `$ J ?6 L: \+ S' E k
摘要号：8005 标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). 报告人：杜鹃 单位：上海长征医院
; @3 |" Z8 P) O1 n* s5 A
肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤
$ ~6 m- S9 b, D% l- U( `4 m Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
" B7 y2 q; T& W3 |7 Y- E' a摘要号：8501 标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. 报告人：陆舜 单位：上海交通大学医学院附属胸科医院 2 ]5 i- l+ L' m, }4 Z
肺癌-转移性非小细胞肺癌
- M' E2 X7 p! S1 `1 n Lung Cancer—Non-Small Cell Metastatic
j. W3 z2 k. g8 `& n) }摘要号：9001 标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. 报告人：吴一龙 单位：广东省人民医院
# K: D2 a$ ?* M& b/ e( f0 F
! m' u: V7 H: K/ @- N
摘要号：9002 标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. 报告人：王孟昭 单位：北京协和医院 9 P' A, f# i1 w2 i q
摘要号：9003 标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations. 报告人：邬麟 单位：湖南省肿瘤医院 ; e# }; m+ ^' ^5 O) w4 ^4 a
黑色素瘤/皮肤癌3 d, e. L. \% [9 m+ }1 e! W+ M4 w9 y
Melanoma/Skin Cancers 摘要号：9508 标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. 报告人：郭军 单位：北京大学肿瘤医院 - `/ @; {/ a: d! v" \" o
快速摘要报告$ c* \4 R& R! ~% r% z
Rapid Abstract Session 摘要号：LBA1013 标题：TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). 报告人：江泽飞 单位：JFJ总医院第五医学中心
" _& l+ E/ K. Q! b. b7 v
临床科学研讨会4 G$ c' [% C# w
Clinical Science Symposium 摘要号：11510 标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma. 报告人：尹军强 单位：中山大学附属第一医院 1 ?! O7 ]* a6 ]( w4 s) V' s- T
% q z$ Z6 G7 q( F) u( j. r | 
发表于 2023-4-28 14:46:30
楼主
发表于 2023-4-28 14:53:34
发表于 2023-4-28 20:42:18
，中肿在保持鼻咽癌和食道癌这些优势的同时，头颈癌和血癌也逐渐发力了
